solute carrier family 35 member A2
Dernière mise à jour 18 Aug 2020
Respecte les directives éditoriales
- TéléchargerTélécharger
- Partager
- Language
- Discussion
- Ask Patient
- Version audio
- Ajouter aux sources préférées sur Google
La SLC35A2 gene provides instructions for making an enzyme called UDP-galactose translocator (UGT). This enzyme is involved in a process called glycosylation. During this process, complex chains of sugar molecules (oligosaccharides) are added to proteins and fats (lipids). Glycosylation modifies proteins and lipids so they can fully perform their functions. The UGT enzyme transfers a simple sugar called galactose to growing oligosaccharides at a particular step in the formation of the sugar chain. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or lipid.
Sélections vidéo pour GènesBibliothèque vidéo
Normal function
La SLC35A2 gene provides instructions for making an enzyme called UDP-galactose translocator (UGT). This enzyme is involved in a process called glycosylation. During this process, complex chains of sugar molecules (oligosaccharides) are added to proteins and fats (lipids). Glycosylation modifies proteins and lipids so they can fully perform their functions. The UGT enzyme transfers a simple sugar called galactose to growing oligosaccharides at a particular step in the formation of the sugar chain. Once the correct number of sugar molecules are linked together, the oligosaccharide is attached to a protein or lipid.
Two versions of the enzyme, known as UGT1 and UGT2, are produced from the SLC35A2 gene. These enzymes differ in only a few protein building blocks (amino acids) and can function together or separately in different areas of the cell.
Conditions referring to this gene or chromosome
Other names
solute carrier family 35 (UDP-galactose transporter), member 2
solute carrier family 35 (UDP-galactose transporter), member A2
UDP-Gal-Tr
UDP-galactose translocator
UGALT
UGAT
UGT
UGT1
UGT2
UGTL
Related patient information and medicines

Patient information leaflet
Mucoviscidose
Qu'est-ce que cystic fibrosis. Cystic fibrosis is a condition which mainly affects the lungs and pancreas but can affect other parts of the body, including the liver, nose and sinuses and sweat glands. Normally, cells in these parts of the body make mucus an... What causes cystic fibrosis. Cystic fibrosis is a genetic disorder. A genetic disorder is one.

Patient information leaflet
Prévoir de devenir enceinte
The aim is to plan ahead to reduce the risk of any harm to the baby and to reduce the risk of la grossesse complications. Women on regular medication, or who have a long-term medical condition, may need to seek medical advice to discuss any changes which may need to be made. There is a summary checklist at the end of the leaflet. However women who.

Patient information leaflet
Maladie polykystique des reins
The two common problems that develop are high blood pressure High blood pressure and chronic kidney disease (CKD) Chronique kidney disease. About half of ADPKD cases lead to kidney failure requiring dialysis or a kidney transplant. What is polycystic kidney disease. A cyst is a fluid-filled sac. Cysts occur in various sizes, in various conditions.

Patient information leaflet
Maladies de stockage du glycogène
Maladies de stockage du glycogène sont a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Newer treatment possibilities.

Patient information leaflet
Glaucome
By the age of 70, about 1 in 33 people in the UK have glaucoma. Glaucoma is unusual in people under the age of 35. Glaucome peuvent affect anyone but it is more common si you: Avoir a family history of glaucoma (if a parent, brother or sister has glaucoma, you are 2-4 times more likely than other people to develop it yourself). Have very short sight..

Patient information leaflet
Trouble lié à l’usage de l’alcool
Some people can find it very difficult to control, or stop, their drinking. What is alcohol use disorder. Alcohol use disorder means drinking alcohol in a way that causes harm. If you or a family member has alcohol use disorder then treatment and support can be provided to help you or your family member reduce or stop drinking alcohol. Alcohol use.
Lectures complémentaires et références
- solute carrier family 35 member A2; MedlinePlus, National Library of Medicine.
- Dorre K, Olczak M, Wada Y, Sosicka P, Gruneberg M, Reunert J, Kurlemann G, Fiedler B, Biskup S, Hortnagel K, Rust S, Marquardt T. A new case of UDP-galactose transporter deficiency (SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach. J Inherit Metab Dis. 2015 Sep;38(5):931-40. doi: 10.1007/s10545-015-9828-6. Epub 2015 Mar 17.
- Kimizu T, Takahashi Y, Oboshi T, Horino A, Koike T, Yoshitomi S, Mori T, Yamaguchi T, Ikeda H, Okamoto N, Nakashima M, Saitsu H, Kato M, Matsumoto N, Imai K. A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy. Brain Dev. 2017 Mar;39(3):256-260. doi: 10.1016/j.braindev.2016.09.009. Epub 2016 Oct 12.
- Kodera H, Nakamura K, Osaka H, Maegaki Y, Haginoya K, Mizumoto S, Kato M, Okamoto N, Iai M, Kondo Y, Nishiyama K, Tsurusaki Y, Nakashima M, Miyake N, Hayasaka K, Sugahara K, Yuasa I, Wada Y, Matsumoto N, Saitsu H. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy. Hum Mutat. 2013 Dec;34(12):1708-14. doi: 10.1002/humu.22446. Epub 2013 Oct 15.
- Ng BG, Buckingham KJ, Raymond K, Kircher M, Turner EH, He M, Smith JD, Eroshkin A, Szybowska M, Losfeld ME, Chong JX, Kozenko M, Li C, Patterson MC, Gilbert RD, Nickerson DA, Shendure J, Bamshad MJ; University of Washington Center for Mendelian Genomics; Freeze HH. Mosaicism of the UDP-galactose transporter SLC35A2 causes a congenital disorder of glycosylation. Am J Hum Genet. 2013 Apr 4;92(4):632-6. doi: 10.1016/j.ajhg.2013.03.012.
Partagez vos pensées ou expériences avec les autres dans notre communautés de patients.
Inscrivez-vous à la newsletter Patient
Votre dose hebdomadaire de conseils de santé clairs et fiables - rédigés pour vous aider à vous sentir informé, confiant et maître de la situation.
En vous abonnant, vous acceptez notre Politique de confidentialité. Vous pouvez vous désabonner à tout moment. Nous ne vendons jamais vos données.

